Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.44 |
| ▸ | PDE4A | P27815 | 6/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945200 | 0.89 | TSHR (0.54) | MAPTSMN1; SMN2GLAADORA2APDE4A | |
| SCHEMBL1944581 | 0.88 | TSHR (0.49) | MAPTSMN1; SMN2ADORA2APDE4APDE4B | |
| SCHEMBL1948128 | 0.85 | ALDH1A1 (0.51) | MAPTSMN1; SMN2GLAADORA2APDE4A | |
| SCHEMBL27617420 | 0.81 | KMT2A (0.37) | SMN1; SMN2HPGDHSD17B10MEN1KMT2A | |
| SCHEMBL5940597 | 0.81 | KMT2A (0.35) | MAPTSMN1; SMN2GLAHPGDTSHR | |
| SCHEMBL1945396 | 0.81 | TSHR (0.36) | MAPTSMN1; SMN2GLAADORA2APDE4A | |
| SCHEMBL1946234 | 0.81 | ALDH1A1 (0.47) | GLAHPGDHSD17B10MEN1KMT2A | |
| SCHEMBL4467734 | 0.79 | TSHR (0.43) | MAPTSMN1; SMN2GLAADORA2APDE4A | |
| SCHEMBL9765877 | 0.79 | SMN1; SMN2 (0.42) | MAPTSMN1; SMN2GLAADORA2APDE4A | |
| SCHEMBL1946973 | 0.79 | ALDH1A1 (0.45) | MAPTHPGDTSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8609671-B2 | Method of inhibiting hepatic fibrosis as a result of liver replacement or repair using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8466129-B2 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466129-B2 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466129-B2 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8324224-B2 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2012-08-30 | — | — | US | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030139428-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003042214-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| US-6002004-A | Pyrrolodiazine derivatives as stabilizers for chilorine-containing polymers | WITCO VINYL ADDITIVES GMBH (DE) | 1999-12-14 | — | — | US | disclosed |
| WO-1999031101-A1 | ADENOSINE RECEPTOR ANTAGONISTS WITH IMPROVED BIOACTIVITY | UNIVERSITY OF SOUTH FLORIDA (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0686155-B1 | XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS | MERRELL PHARMA INC (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5770643-A | Pyrrolodiazine derivatives as stabilizers for chlorine-containing polymers | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0449175-B1 | Selective adenosine receptor agents | MERRELL PHARMA INC (US) | 1997-07-30 | — | — | EP | disclosed |
| EP-0736569-A1 | Derivatives of pyrrolodiazine as stabilisers for polymers containing chlorine | CIBA-GEIGY AG (CH) | 1996-10-09 | — | — | EP | disclosed |
| EP-0449175-A2 | Selective adenosine receptor agents | MERRELL PHARMACEUTICALS INC. (US) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | MAPT 4844/4885SMN1; SMN2 4408/4885GLA 2545/4885 |
| US-20030139428-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | MAPT 4828/4885SMN1; SMN2 3610/4885GLA 3531/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | MAPT 4828/4885SMN1; SMN2 3610/4885GLA 3531/4885 |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | MAPT 4844/4885SMN1; SMN2 4408/4885GLA 2545/4885 |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | MAPT 4833/4885SMN1; SMN2 3610/4885GLA 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.